Epithelial growth factor receptor (EGFR) is a cell surface transmembrane receptor that
mediates the tyrosine signaling pathway to carry the extracellular messages inside the cell …

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) are
standard of care in the first-line (1L) setting for patients with metastatic non–small cell lung …

Owing to aging populations, the prevalence of hypertension and associated cardiovascular
events has been increasing worldwide. The morbidity and mortality due to cancer have also …

Tumor necrosis factor (TNF) and its receptors are widely expressed in non-small cell lung
cancer (NSCLC). TNF has an established role in inflammation and also plays a key role in …

Lung cancer is the second most common cause of morbidity and mortality among cancer
types worldwide, with non-small cell lung cancer (NSCLC) representing the majority of most …

Purpose: In EGFR-mutated metastatic non–small cell lung cancer (NSCLC), outcomes from
EGFR tyrosine kinase inhibitors have differed historically by mutation type present, with …

Three generations of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-
TKIs) have been developed for treating advanced/metastatic non-small cell lung cancer …

Aims EGFR and VEGFR-2 have emerged as promising targets for cancer management as
they play a crucial role in tumor growth, angiogenesis and metastasis. A novel series of 2 …

Purpose Liver metastasis (LM) is common in non-small cell lung cancer (NSCLC), and
always predicted worse outcomes with no effective therapy. We aimed to evaluate the effects …

The objective of this systematic review and meta-analysis was to assess and contrast the
efficacy and safety of combining erlotinib and bevacizumab with erlotinib alone in the …